Analyst Price Target is $36.25
▲ +46.41% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Century Therapeutics in the last 3 months. The average price target is $36.25, with a high forecast of $40.00 and a low forecast of $33.00. The average price target represents a 46.41% upside from the last price of $24.76.
Current Consensus is
The current consensus among 4 polled investment analysts is to buy stock in Century Therapeutics.
Century Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company's lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 for relapsed, refractory B-cell lymphoma. It is also developing CNTY-103, a CAR-iNK candidate targeting CD133 + EGFR for recurrent glioblastoma; CNTY-102, a CAR-iT or CAR-iNK candidate targeting CD19 + CD79b for relapsed, refractory B-cell lymphoma and other B-cell malignancies; and CNTY-104, a CAR-iT or CAR-iNK multi-specific candidate for acute myeloid leukemia. The company was founded in 2018 and is headquartered in Philadelphia, Pennsylvania.